早期与延迟Pegcetacoplan治疗地图样萎缩的疗效比较:OAKS、DERBY和GALE研究
基于OAKS、DERBY和GALE研究,比较早期与延迟Pegcetacoplan治疗继发于年龄相关性黄斑变性的地图样萎缩的疗效及48个月安全性。结果显示持续48个月治疗较预估假手术组降低GA面积增长率最高达24%,早期治疗组非中心凹下GA保留的视网膜组织约为延迟治疗组的3倍。长期解剖和功能结局支持早期治疗以最大程度保留视网膜组织和功能。
要点
- 持续48个月Pegcetacoplan治疗降低GA面积增长率最高达24%,相当于保留1.88 mm²视网膜组织。
- 非中心凹下GA早期治疗组保留视网膜组织(每月治疗最高3.16 mm²)约为延迟治疗组(1.11 mm²)的3倍。
- 总体人群进展为绝对暗点的风险降低:全部中央4个位点降低32%,16个位点降低43%。
核心结论
- Pegcetacoplan在48个月内显示减缓GA进展的有效性和一致的安全性。
- 长期解剖和功能结局支持早期治疗以最大程度保留视网膜组织和功能。
研究设计与样本
- 分析III期OAKS和DERBY研究的III期GALE开放标签扩展(OLE)的疗效和安全性数据,代表最长48个月持续Pegcetacoplan治疗。
- 早期治疗组:在OAKS、DERBY和GALE研究中接受Pegcetacoplan治疗48个月的眼睛;延迟治疗组:OAKS和DERBY中假手术观察的眼睛在24个月时 crossover 至GALE接受Pegcetacoplan治疗24个月。
主要发现
- 总体人群中,48个月持续Pegcetacoplan治疗较预估假手术降低GA面积增长率最高达24%,相当于1.88 mm²视网膜组织。
- 非中心凹下GA早期治疗组保留的视网膜组织(每月治疗最高3.16 mm²)约为延迟治疗组(1.11 mm²)的3倍。
- 总体人群中观察到进展为全部中央4个和16个位点绝对暗点的风险降低(分别32%和43%)。
- GALE安全性数据与OAKS和DERBY研究结果一致。
临床怎么用
- 对于继发于年龄相关性黄斑变性的地图样萎缩,早期启动Pegcetacoplan治疗可能比延迟治疗保留更多视网膜组织和功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the efficacy of early versus delayed pegcetacoplan treatment in eyes with geographic atrophy (GA) secondary to age-related macular degeneration as well as the 48-month safety profile of pegcetacoplan. DESIGN: Efficacy and safety data from the phase 3 GALE open-label extension (OLE) of the phase 3 OAKS and DERBY studies, representing up to 48 months of continuous pegcetacoplan treatment, were analyzed. PARTICIPANTS: Eyes with nonsubfoveal or subfoveal GA receiving pegcetacoplan in OAKS and DERBY continued receiving pegcetacoplan at the same dosing regimen in GALE, and sham-observed eyes with nonsubfoveal or subfoveal GA in OAKS and DERBY crossed over to active treatment in GALE at the same dosing interval in those studies. METHODS: The overall population included eyes with nonsubfoveal GA and eyes with subfoveal GA. Subgroup analyses were performed on data from eyes with nonsubfoveal GA and eyes with subfoveal GA. The early treatment group comprised eyes receiving pegcetacoplan for 48 months across the OAKS, DERBY, and GALE studies. The delayed treatment group included sham-observed eyes from OAKS and DERBY which crossed over at 24 months to receive pegcetacoplan treatment for 24 months in the GALE OLE. MAIN OUTCOME MEASURES: GA area growth rate, amount of retinal tissue preserved, risk of progression to absolute scotoma, and safety. RESULTS: In the overall population, 48 continuous months of pegcetacoplan treatment reduced GA area growth rate by up to 24% compared with projected sham, translating to 1.88 mm2 of retinal tissue. Approximately 3 times more retinal tissue (up to 3.16 mm2 with monthly treatment) was preserved in eyes with nonsubfoveal GA in the early treatment group compared with eyes in the nonsubfoveal GA delayed treatment group (1.11 mm2). Reduced risk of progression to absolute scotoma of all central 4 and 16 loci (32% and 43%, respectively) was observed in the overall population. GALE safety data were consistent with the findings of the OAKS and DERBY studies. CONCLUSIONS: Pegcetacoplan demonstrated effectiveness in slowing GA progression and consistent safety over 48 months. Long-term anatomic and functional outcomes support the importance of early treatment to maximize the preservation of retinal tissue and function.
引用
- Dhoot DS, Singerman LJ, Ferrone PJ, et al. Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE. Am J Ophthalmol. 2026. PMID: 42665201. doi:10.1016/j.ajo.2026.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。